X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
http://www.pharmatimes.com/news/eu_oks_paediatric_use_of_gileads_epclusa_1347616
https://www.gilead.com/news-and-press/press-room/press-releases/2020/8/gilead-announces-presentation-of-more-than-40-abstracts-from-extensive-liver-disease-programs-at-the-digital-international-liver-congress-2020
https://www.in-pharmatechnologist.com/Article/2019/09/30/AbbVie-receives-approval-HCV-treatment
https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and
https://www.biopharmadive.com/news/fda-safety-warning-hepatitis-c-drugs-patient-deaths/561891/
https://www.contractpharma.com/contents/view_breaking-news/2019-05-29/particle-sciences-expands-controlled-substance-capabilities/
https://www.fiercepharma.com/pharma/louisiana-picks-gilead-subsidiary-to-partner-netflix-model-for-hep-c-drugs
https://www.gilead.com/news-and-press/press-room/press-releases/2019/1/japans-ministry-of-health-labour-and-welfare-approves-gileads-epclusa-sofosbuvirvelpatasvir
https://www.fiercepharma.com/marketing/abbvie-highlights-mavyret-s-8-week-advantage-new-ad-campaign-as-it-continues-its-hep-c
https://endpts.com/what-do-martin-shkreli-gilead-and-takeda-have-in-common-they-all-figure-prominently-in-the-new-top-20-list-of-the-worlds-most-expensive-drugs/
https://www.biopharmadive.com/news/express-scripts-flex-formulary-gilead-authorized-alternatives/542259/
http://www.pharmatimes.com/news/gilead_raises_outlook_despite_dip_in_revenue_1257213
https://www.bloomberg.com/news/articles/2018-09-24/gilead-to-sell-cheaper-versions-of-drug-that-sparked-cost-debate
https://www.reuters.com/article/us-gilead-sciences-genericdrugs/gilead-to-launch-generic-versions-of-its-hepatitis-drugs-idUSKCN1M42H6
https://www.raps.org/news-and-articles/news-articles/2018/9/fda-issues-54-new-and-revised-product-specific-gui?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2013%20September
https://endpts.com/gilead-loses-key-patent-claims-for-sovaldi-in-china-opening-door-to-earlier-generic-entry/
https://www.thehindubusinessline.com/companies/two-pre-grant-patent-oppositions-filed-on-gileads-hepatitis-c-medicines/article24377414.ece
https://www.forbes.com/sites/nicolefisher/2018/06/26/sticker-shock-the-real-cost-of-americas-10-most-expensive-drugs/?ss=pharma-healthcare#1781663714d1
https://www.fiercepharma.com/pharma-asia/gilead-wins-chinese-approval-for-epclusa-but-emerging-market-getting-crowded
http://www.pmlive.com/pharma_news/gilead_wins_european_approval_for_triple_hep_c_combination_vosevi_1209554
https://www.pharmacompass.com/pdf/news/gileads-vosevi-sofosbuvirvelpatasvirvoxilaprevi-receives-approval-in-europe-1506163765.pdf
http://www.fiercepharma.com/pharma/gilead-wins-blockbuster-approval-for-hep-c-trio-vosevi-but-will-12-week-dosing-give-it
http://www.raps.org/Regulatory-Focus/News/2017/06/23/27961/EMA-Recommends-New-HCV-Cancer-and-MS-Drugs-for-Approval/?utm_source=Email&utm_medium=Informz&utm_campaign=Informz-Emails
http://www.raps.org/Regulatory-Focus/News/2017/06/06/27845/WHO-Essential-Medicines-Update-Adds-Antibiotic-use-Framework-and-new-HCV--HIV-Drugs/?utm_source=Email&utm_medium=Informz&utm_campaign=Informz-Emails
http://www.business-standard.com/article/companies/natco-pharma-launches-generic-hepatitis-c-drug-in-india-117050800391_1.html
http://economictimes.indiatimes.com/news/industry/healthcare/biotech/pharmaceuticals/hetero-gets-dcgi-nod-for-generic-chronic-hepatitis-c-drug/articleshow/58531020.cms
http://www.pharmamanufacturing.com/industrynews/2017/fda-approves-first-hep-c-drugs-for-kids/
http://www.biospace.com/News/how-gilead-just-lost-9-billion-in-market-value/446267/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.fiercepharma.com/pharma/value-investors-pile-into-gilead-expecting-strong-long-term-growth-report
http://www.pharmatimes.com/news/final_yes_from_nice_for_gileads_epclusa_1185110
http://www.pmlive.com/pharma_news/two_new_hepatitis_c_therapies_fast-tracked_in_europe_1184949
http://www.gilead.com/news/press-releases/2017/1/european-medicines-agency-validates-gileads-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-sofosbuvirvelpatasvirvoxilaprevir-sofvelvox
http://www.biospace.com/News/gileads-rd-woes-could-make-it-an-attractive-target/439689/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.fiercepharma.com/marketing/abbvie-s-pan-genotypic-hep-c-prospect-shines-trials-putting-heat-rival-gilead
http://www.pharmatimes.com/news/smc_endorses_use_of_five_meds_on_nhs_scotland_1175885
http://www.drug-dev.com/Main/Back-Issues/HCV-MARKET-Recent-Success-in-HCV-Treatment-Brings-1213.aspx
http://www.fiercebiotech.com/biotech/gilead-drops-pah-dkd-tests-after-phii-failure-highlights-positive-noises-for-nash
http://www.pharmatimes.com/news/eu_clears_gileads_pan-genotypic_hepatitis_c_therapy_1076700
Market Place
Share 
